PharmiNews

The Directory of Pharma Companies and News

Teva

Teva logo
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion.
Category: Pharmaco
Category: Pharmaco

Teva News

DateNews
2017-08-03Teva Reports Second Quarter 2017 Financial Results
2017-07-31Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Herceptin® ...
2017-07-28Teva Announces Launch of Generic Epiduo® in the United States
2017-07-24Teva Announces the Launch of Generic Vagifem® in the United States
2017-07-20NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma
2017-07-13Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders
2017-07-11Teva to Report Second Quarter 2017 Financial Results on August 3, 2017
2017-07-11Teva and the Huntington Study Group Announce Publication of Data for AUSTEDOâ„¢ (deutetrabenazine) Tablets in Huntington...
2017-06-29Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (r...
2017-06-29Teva Announces Publication of AIM-TD Study Results in The Lancet Psychiatry for the Investigational Use of Deutetrabenaz...
2017-06-27Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet P...
2017-06-12Teva Announces Launch of Generic Zetia® in the United States
2017-06-09Teva Announces Exclusive Launch of Generic Pataday® in the United States
2017-06-07Teva's Fremanezumab Meets all Primary & Secondary Endpoints Across Both Monthly and Quarterly Dosing Regimens in Phase I...
2017-06-06Teva to Present at the Jefferies 2017 Global Healthcare Conference
2017-05-17Teva Showcases Asthma Research at the 2017 American Thoracic Society (ATS) International Conference
2017-05-17Teva to Present Data for Deutetrabenazine in Tardive Dyskinesia at the American Psychiatric Association 2017 Annual Meet...
2017-05-15Teva Announces Launch of Generic Glumetza® in the United States
2017-05-15Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
2017-05-11Teva Reports First Quarter 2017 Financial Results
2017-05-05Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint
2017-05-05Teva Announces Publication of COPAXONE® (glatiramer acetate injection) Pregnancy Data in the International Journal of M...
2017-04-27Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tar...
2017-04-26Teva Announces Launch of Generic Vytorin® in the United States
2017-04-26Teva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial Officer
2017-04-20Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salm...
2017-04-19Teva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of Neurology
2017-04-06Teva to Report First Quarter 2017 Financial Results on May 11, 2017
2017-04-03Teva Announces FDA Approval of AUSTEDOâ„¢ (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Hunting...
2017-03-16Teva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate and ethinyl estradiol tablets an...
2017-03-13Teva to Present at the Barclays Global Annual Healthcare Conference
2017-03-06Teva to Present at the Cowen & Company 37th Annual Healthcare Conference
2017-01-09Teva Announces Completion of Sale of UK and Ireland Actavis Assets and Operations Following European Commission Approval
2017-01-06Teva to Present at the 35th Annual J.P. Morgan Healthcare Conference
2017-01-06Teva Provides 2017 Financial Outlook
2017-01-05Teva to Host 2017 Business Outlook Conference Call and Webcast on January 6, 2017
2016-12-22Teva Reaches Settlement with Government on FCPA
2016-12-07Teva to Present at the Citi 2016 Global Healthcare Conference
2016-12-06Teva Receives Positive Outcome for COPAXONE® Label in Europe
2016-12-05Teva Appoints Dipankar Bhattacharjee as President and Chief Executive Officer, Global Generic Medicines Group, Succeedin...
2016-11-30Teva to Present Oncology Data at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition
2016-11-21Teva Secures European Approval of Trisenox® for First Line Treatment of Low to Intermediate Risk Acute Promyelocytic Le...
2016-09-28Teva Announces Launch of Generic Epzicom® Tablets in the United States
2016-09-22Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)
2016-09-20Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody...
2016-09-19Teva Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study of Pridopidine in Huntington Disease
2016-09-15Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin® (Daptomycin for Injection) ...
2016-09-15Teva to Develop Unique Wearable Tech and Machine Learning Platform for Continuous Measurement & Analysis of Huntington D...
2016-09-07Teva to Present Latest Data in Multiple Sclerosis at 2016 ECTRIMS Congress in London
2016-09-06Teva to Present at the Wells Fargo 2016 Healthcare Conference
2016-08-30Teva to Present New Respiratory Data at the 2016 European Respiratory Society (ERS) International Congress
2016-08-29Teva to Host Generic Medicines Business Overview on September 9, 2016
2016-08-24Teva Confirms PTAB’s Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg
2016-08-18European Commission Grants Marketing Authorization for Teva’s CINQAERO® (reslizumab)
2016-08-05Teva Announces Launch of Generic Gleevec® Tablets in the United States
2016-08-04Teva Reports Second Quarter 2016 Results
2016-08-03Teva Announces Acquisition of Anda Inc.
2016-08-02Teva Completes Acquisition of Actavis Generics
2016-07-27Teva to Report Second Quarter 2016 Financial Results on August 4, 2016
2016-07-27Teva Receives Clearance from the U.S. Federal Trade Commission for Actavis Generics Acquisition
2016-07-21Teva Announces Pricing of Additional CHF1.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Ge...
2016-07-20Teva Announces Pricing of Additional €4.0 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Ge...
2016-07-18Teva Announces Pricing of $15 Billion of Senior Notes in Connection with Pending Acquisition of Actavis Generics
2016-07-12Teva to Host Conference Call and Webcast to Provide Preliminary Outlook for 2016-2019
2016-07-05Teva and the Huntington Study Group Announce Publication of Pivotal Phase III Data on Deutetrabenazine (SD-809) in Hunti...
2016-06-28Teva Announces FDA Acceptance of New Drug Applications for Fluticasone Propionate/Salmeterol and Fluticasone Propionate ...
2016-06-27Teva and Antares Pharma Announce Launch of Generic Imitrex® in the United States
2016-06-24Teva Receives CHMP Positive Opinion for CINQAERO® (reslizumab)
2016-06-23Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatid...
2016-06-20Teva CEO Erez Vigodman speaks at 2016 SelectUSA Investment Summit
2016-06-20Teva to Present Data Highlighting SD-809 at 20th International Congress of Parkinson’s Disease and Movement Disorders
2016-06-13Teva Announces Voluntary Suspension of Marketing for ZECUITY® in the U.S.
2016-06-10Teva Announces Favorable Court Ruling in TREANDA® (bendamustine hydrochloride) Patent Infringement Litigation
2016-06-07Teva to Present at the Jefferies 2016 Healthcare Conference
2016-06-07Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELAâ„¢ ER (hydrocodone bitartrate) Extended...
2016-06-06Teva to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
2016-05-31Teva to Present at the Bernstein 32nd Annual Strategic Decisions Conference
2016-05-31Teva Receives Complete Response Letter for NDA for SD-809 for the Treatment of Chorea Associated with Huntington Disease
2016-05-12Teva to Present New Data at the 2016 American Thoracic Society (ATS) International Conference
2016-05-09Teva Reports First Quarter 2016 Results
2016-05-09Teva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
2016-05-04Teva Breathes Its Way to a Guinness World Records Title
2016-04-29Teva Announces FDA Approval of ProAir RespiClick® (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients A...
2016-04-25Jennifer Morrison Reveals How Her Journey with Migraine is More Than a Headache
2016-04-18Teva to Report First Quarter 2016 Financial Results on May 9, 2016
2016-04-18Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Va...
2016-04-12Teva to Present Data Highlighting Company’s Pipeline in Neurological Disorders at 68th AAN Annual Meeting
2016-03-31Takeda and Teva Establish “Teva Takeda Yakuhin Ltd.� in Japan
2016-03-23Teva Announces FDA Approval of CINQAIR® (reslizumab) Injection
2016-03-22Teva Announces Launch of Generic Campral® in the United States
2016-03-10Teva Receives European Commission Approval for the Allergan Generics Acquisition
2016-03-09Teva Completes Generic Pulmicort® Respules Portfolio with the Launch of Third Strength in the United States
2016-03-03Teva Completes Acquisition of Rimsa
2016-03-03Teva to Present New Respiratory Data at the 2016 Academy of Allergy, Asthma and Immunology Annual Meeting
2016-03-02Teva to Present at the Cowen & Company 36th Annual Healthcare Conference
2016-02-24Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand
2016-02-11Teva Reports Full Year 2015 and Fourth Quarter Financial Results
2016-02-11Teva Files 2015 Annual Report on Form 20-F
2016-02-02Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
2016-01-28Teva to Report Fourth Quarter 2015 Financial Results on February 11, 2016
2016-01-28Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKAâ„¢ (bendamustine hydrochloride) Injection
2016-01-25Teva Releases Innovation and Social Responsibility Highlights
2016-01-07Teva and Checkpoint Therapeutics Announce License Agreement for Oral PARP Inhibitor
2016-01-07Teva to Present at the 34th Annual J.P. Morgan Healthcare Conference
2016-01-05Teva Announces Launch of Generic Ortho Tri-Cyclen® Lo in the United States
2016-01-04Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials
2016-01-03Teva Announces Exercise of Underwriters’ Over-Allotment Option
2015-12-27INSERTING and REPLACING Takeda Provides Further Information about its New Business Venture with Teva
2015-12-27Takeda Provides Further Information about its New Business Venture with Teva
2015-12-10FDA Advisory Committee Recommends Approval of Teva’s Asthma Biologic Reslizumab
2015-12-08Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKAâ„¢ (bendamustine hydrochloride) Injectio...
2015-12-08Teva Announces Closing of Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in C...
2015-12-02Teva Announces Pricing of Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in C...
2015-11-30Teva and Takeda Establish Unique Partnership to Meet the Wide-Ranging Needs of Patients and Growing Importance of Generi...
2015-11-30Teva Announces Proposed Public Offerings of American Depositary Shares and Mandatory Convertible Preferred Shares in Con...
2015-11-25Teva and Heptares Enter Agreement to Discover and Develop Novel, Small-Molecule CGRP Antagonists for Treatment of Migrai...
2015-11-19Teva and University College London Embark on Unique Brain Imaging Study Aimed at Unlocking a New Approach in Neurodegene...
2015-11-19Teva Reports Positive Top-Line Results from Phase III Trials Evaluating Fluticasone Propionate/Salmeterol and Fluticason...
2015-11-17Teva to Present at the Jefferies Autumn 2015 Global Healthcare Conference
2015-11-09Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia
2015-11-04Teva to Present New Respiratory Data at the 2015 Annual Scientific Meeting of the American College of Allergy, Asthma an...
2015-11-02Teva’s Statement on its Internal Specialty Pharmacy
2015-10-29Teva Reports Third Quarter 2015 Results
2015-10-15Teva to Host Third Quarter 2015 Financial Results Conference Call and Webcast on October 29, 2015
2015-10-12Teva Announces Exclusive Launch of Generic Avodart® Capsules in the United States
2015-10-08Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Mul...
2015-10-06Teva Reinforces Focus on Advancing Multiple Sclerosis Treatment at 31st ECTRIMS Congress
2015-10-01Teva Accelerates its Emerging Markets Growth Strategy with the Acquisition of Rimsa, a Leading Independent Pharmaceutica...
2015-09-30Important New Data from Teva's TEV-48125 Phase 2B Migraine Program Published in Lancet Neurology in Back-to-Back Article...
2015-09-28Teva Announces Approval of COPAXONE® in Japan for the Prevention of Relapse of Multiple Sclerosis
2015-09-27Teva Presents New Reslizumab Data at European Respiratory Society (ERS) International Congress 2015
2015-09-25Teva Reinforces Leadership Position in Respiratory with Acquisition of Gecko Health Innovations
2015-09-10Teva Announces FDA Acceptance of a Supplemental New Drug Application for ProAir® RespiClick (albuterol sulfate) Inhalat...
2015-09-10Teva Pharmaceuticals and IBM Partner to Build Global e-Health Solutions on the IBM Watson Health Cloud
2015-09-08Teva Introduces “Design for Dialogue� to Support Patient-Doctor Conversations on Responsible Pain Management
2015-09-01Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic transdermal system), First and Only Transdermal...
2015-08-12Teva Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease
2015-08-03Teva and Immuneering Announce Teva’s Purchase of 51% Equity Share of Genomic-Analysis Company
2015-07-31Teva Secures $33.75 Billion Financing Commitment
2015-07-30Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015
2015-07-28Teva Announces European Medicines Agency (EMA) Confirms Successful Validation of Reslizumab Marketing Authorization Appl...
2015-07-27Teva Reports Preliminary Second Quarter 2015 Results
2015-07-27Teva Withdraws Proposal to Acquire Mylan
2015-07-27Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty Company Well Positi...
2015-07-23Teva Issues Statement
2015-07-23Teva Launches Educational Initiative to Arm Women with Facts about Emergency Contraception
2015-07-21Teva to Report Second Quarter 2015 Financial Results on July 30, 2015
2015-07-08Teva First to Receive Approval and Launch Generic Axert® Tablets in the United States
2015-07-01Teva Launches Generic Aggrenox® Capsules in the United States
2015-07-01Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain
2015-06-25Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial
2015-06-19Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V.
2015-06-18Teva to Present New Findings at the American Headache Society (AHS) Meeting – Analysis of Migraine Phase IIb Studies P...
2015-06-18Teva and Microchips Biotech Announce Partnership to Enhance Patient Outcomes through Digital Drug Delivery Technology
2015-06-16Teva Advances Pipeline of Movement Disorder Assets with Announcement of Positive Top-Line Data from the First Pivotal St...
2015-06-15Teva Announces FDA Acceptance of the Biologics License Application for Reslizumab
2015-06-09Teva to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
2015-06-02Teva Enhances ADHD Product Line with Generic INTUNIV® in the United States
2015-06-01Teva Announces Exclusive Launch of Generic Actonel® Tablets in the United States
2015-05-29Teva Enhances Extensive Women’s Health Portfolio with Launch of Generic Lomedia® 24 Fe Tablets
2015-05-27Jack Osbourne and Teva Launch Enhanced You Don’t Know Jack About MS® Website Featuring New Multimedia Content
2015-05-15Teva to Present New Respiratory Data at 2015 Annual International Meeting of the American Thoracic Society
2015-05-14Teva Presents Further Data from Phase IIb with TEV-48125 in Chronic Migraine at the International Headache Society Congr...
2015-05-08Teva to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
2015-05-05Teva Provides Additional Detail on Proposed Acquisition of Mylan
2015-05-05Teva Completes Acquisition of Auspex Pharmaceuticals
2015-04-30Teva Reports First Quarter 2015 Results
2015-04-29Teva Sends Letter to Mylan Board
2015-04-28Teva Continues to Invigorate Injectable Portfolio with the Launch of Argatroban Injection in the United States
2015-04-28Teva Launches Generic Abilify® Tablets in the United States
2015-04-27Teva Reiterates Commitment to Cash-and-Stock Acquisition of Mylan for $82.00 Per Share
2015-04-23Teva Presents Data Comparing Early Treatment with COPAXONE® 40 mg/mL to Delayed Start Treatment at 67th American Academ...
2015-04-23Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive ...
2015-04-22Teva Files for Hart-Scott-Rodino Notification Regarding Proposed Acquisition of Mylan
2015-04-21Teva Proposes to Acquire Mylan for $82.00 Per Share in Cash and Stock
2015-04-17Teva to Report First Quarter 2015 Financial Results on April 30, 2015
2015-04-14Teva and Eagle Pharmaceuticals Announce NDA for Bendamustine Rapid Infusion Product Accepted for Filing
2015-04-13Teva to Present Multiple Sclerosis Data at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
2015-04-02Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia (...
2015-04-01Teva Announces FDA Approval of ProAir® RespiClick
2015-03-31Teva Expands Hypertension Line with Launch of Generic Exforge® Tablets in the United States
2015-03-30Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
2015-03-24Teva Announces Pricing of €2 Billion of Senior Notes
2015-03-23Teva Announces New Head of Business Development, Strategy and Innovation
2015-03-23Teva’s TEV-48125 Meets Primary and Secondary Endpoints in Episodic Migraine Study, Demonstrating Treatment Concept Aft...
2015-03-17Teva and Ignyta Announce Acquisition by Ignyta of Four Oncology R&D Assets from Teva
2015-03-05Teva to Present at the Barclays Global Healthcare Conference
2015-03-02Teva Announces Sale of Sellersville, PA Facility
2015-02-27Teva Announces Early Results of Debt Tender Offer, Pricing, Election of Early Settlement and Increase in Maximum Amount ...
2015-02-26Teva to Present at the Cowen & Company 35th Annual Healthcare Conference
2015-02-25Teva Announces FDA Acceptance for Review of NDA for its Investigational Twice-Daily Hydrocodone Bitartrate Extended-Rele...
2015-02-24Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoint...
2015-02-23The Lancet Respiratory Medicine and AAAAI Publish Positive Data from Phase III Trials of Teva’s Reslizumab for the Tre...
2015-02-20Teva to Present New Respiratory Data at 2015 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
2015-02-17Teva Bolsters Injectable Portfolio with Launch of Generic Lovenox® and Generic Zyvox® in the United States
2015-02-17Teva and Eagle Pharmaceuticals Announce Teva’s License to Commercialize Eagle’s Bendamustine Rapid Infusion Product
2015-02-12Teva Announces $1 Billion Debt Tender Offer
2015-02-10Teva Files 2014 Annual Report on Form 20-F
2015-02-05Teva Reports Fourth Quarter and Full Year 2014 Results
2015-02-05Teva Thanks Dr. Phillip Frost for Board Service
2015-01-26Teva Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States
2015-01-20Teva Announces U.S. Supreme Court Decision to Reverse Federal Circuit Court’s Judgment on COPAXONE® 20 mg/mL Case and...
2015-01-15Teva to Report Fourth Quarter 2014 Financial Results on February 5, 2015
1970-01-01Servier and Neurochlore join forces to treat autism in children
1970-01-01Cessation of marketing of Protelos/Osseor: Extract of the letter sent to European Medicine Agency (EMA) and national Eur...
1970-01-01Servier and GAIA extend their partnership to provide patients around the world with deprexis®, an internet-based cogniti...
1970-01-01Mundipharma and Medical Developments International announce a new alliance for the commercialisation of Penthrox\u003csu... (PDF)
1970-01-01Mundipharma secures distribution license for first biosimilar monoclonal antibody \u003cstrong\u003eRemsima\u003c/strong... (PDF)
1970-01-01\u003cstrong\u003eNew data show Truxima® (CT-P10) to have comparable efficacy and tolerability in advanced follicular ly... (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.